Diabetic Peripheral Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Diabetic Peripheral Neuropathy Pipeline Drugs Market Overview
Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legs, and feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain or discomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tone in the feet and lower legs, loss of balance, dry feet, and cracked skin. The predisposing factors include diabetes, smoking, and kidney diseases. Treatment includes antidepressants, anti-seizure, and opioid analgesics.
The Diabetic Peripheral Neuropathy pipeline drugs market research report provide comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects.
Key Targets in the Diabetic Peripheral Neuropathy Pipeline Drugs Market
The key targets in the Diabetic Peripheral Neuropathy pipeline drugs market are Transient Receptor Potential Cation Channel Subfamily V Member 1, Aldose Reductase, Heat Shock Protein 90, Muscarinic Acetylcholine Receptor M1, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, Bifunctional Epoxide Hydrolase 2, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Free Radical, and others.
Diabetic Peripheral Neuropathy Pipeline drugs Market Analysis by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Diabetic Peripheral Neuropathy Pipeline Products Market
The key mechanisms of action in the Diabetic Peripheral Neuropathy pipeline products market are Aldose Reductase Inhibitor, Heat Shock Protein 90 Inhibitor, Muscarinic Acetylcholine Receptor M1 Antagonist, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Transient Receptor Potential Cation Channel Subfamily V Member 1 Activator, Bifunctional Epoxide Hydrolase 2 Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Free Radical Scavenger, and others.
Diabetic Peripheral Neuropathy Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
Key Routes of Administration in the Diabetic Peripheral Neuropathy Pipeline Drugs Market
The key routes of administration in the Diabetic Peripheral Neuropathy pipeline drugs market are oral, topical, intramuscular, intravenous drip, subcutaneous, sublingual, and transdermal.
Diabetic Peripheral Neuropathy Pipeline Drugs Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Diabetic Peripheral Neuropathy Pipeline Products Market
The key molecule types in the Diabetic Peripheral Neuropathy pipeline products market are small molecule, cell therapy, gene therapy, and recombinant protein.
Diabetic Peripheral Neuropathy Pipeline Products Market Analysis by Molecule Type
For more molecule type insights, download a free report sample
Major Companies in the Diabetic Peripheral Neuropathy Pipeline Products Market
Some of the major companies in the Diabetic Peripheral Neuropathy pipeline products market are Praetego Inc, Medifron DBT Co Ltd, Reata Pharmaceuticals Inc, Winsantor Inc, Achelios Therapeutics Inc, Annji Pharmaceutical Co Ltd, Applied Therapeutics Inc, Celularity Inc, CSPC Pharmaceutical Group Ltd, and Exodos Life Sciences Limited Partnership.
Diabetic Peripheral Neuropathy Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Overview
Key targets | Transient Receptor Potential Cation Channel Subfamily V Member 1, Aldose Reductase, Heat Shock Protein 90, Muscarinic Acetylcholine Receptor M1, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, Bifunctional Epoxide Hydrolase 2, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Free Radical, and Others |
Key mechanism of action | Aldose Reductase Inhibitor, Heat Shock Protein 90 Inhibitor, Muscarinic Acetylcholine Receptor M1 Antagonist, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Transient Receptor Potential Cation Channel Subfamily V Member 1 Activator, Bifunctional Epoxide Hydrolase 2 Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Free Radical Scavenger, and others |
Key routes of administration | Oral, Topical, Intramuscular, Intravenous Drip, Subcutaneous, Sublingual, and Transdermal |
Key molecule type | Small Molecule, Cell Therapy, Gene Therapy, and Recombinant Protein |
Major companies | Praetego Inc, Medifron DBT Co Ltd, Reata Pharmaceuticals Inc, Winsantor Inc, Achelios Therapeutics Inc, Annji Pharmaceutical Co Ltd, Applied Therapeutics Inc, Celularity Inc, CSPC Pharmaceutical Group Ltd, and Exodos Life Sciences Limited Partnership |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Annji Pharmaceutical Co Ltd
Applied Therapeutics Inc
Celularity Inc
CSPC Pharmaceutical Group Ltd
Exodos Life Sciences Limited Partnership
G&P Bioscience Co Ltd
GNT Pharma Co Ltd
Grunenthal GmbH
Immune Pharmaceuticals Inc
Ion Channel Pharmacology LLC
Jiangsu Aosaikang Pharmaceutical Co Ltd
Korea United Pharm Inc
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Palisade Bio, Inc
Praetego Inc
Pure Green Pharmaceuticals Inc
Reata Pharmaceuticals Inc
Shandong Huizhi Pharmaceutical Technology Co Ltd
Sonnet BioTherapeutics Holdings Inc
Sphaera Pharma Pte Ltd
Winsantor Inc
Zhejiang Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Diabetic Peripheral Neuropathy pipeline products market?
The key targets in the Diabetic Peripheral Neuropathy pipeline products market are Transient Receptor Potential Cation Channel Subfamily V Member 1, Aldose Reductase, Heat Shock Protein 90, Muscarinic Acetylcholine Receptor M1, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, Bifunctional Epoxide Hydrolase 2, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Free Radical, and others.
-
What are the key mechanisms of action in the Diabetic Peripheral Neuropathy pipeline products market?
The key mechanisms of action in the Diabetic Peripheral Neuropathy pipeline products market are Aldose Reductase Inhibitor, Heat Shock Protein 90 Inhibitor, Muscarinic Acetylcholine Receptor M1 Antagonist, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Transient Receptor Potential Cation Channel Subfamily V Member 1 Activator, Bifunctional Epoxide Hydrolase 2 Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Free Radical Scavenger, and others.
-
What are the key routes of administration in the Diabetic Peripheral Neuropathy pipeline products market?
The key routes of administration in the Diabetic Peripheral Neuropathy pipeline products market are oral, topical, intramuscular, intravenous drip, subcutaneous, sublingual, and transdermal.
-
What are the key molecule types in the Diabetic Peripheral Neuropathy pipeline products market?
The key molecule types in the Diabetic Peripheral Neuropathy pipeline products market are small molecule, cell therapy, gene therapy, and recombinant protein.
-
Which are the major companies in the Diabetic Peripheral Neuropathy pipeline products market?
Some of the major companies in the Diabetic Peripheral Neuropathy pipeline products market are Praetego Inc, Medifron DBT Co Ltd, Reata Pharmaceuticals Inc, Winsantor Inc, Achelios Therapeutics Inc, Annji Pharmaceutical Co Ltd, Applied Therapeutics Inc, Celularity Inc, CSPC Pharmaceutical Group Ltd, and Exodos Life Sciences Limited Partnership.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.